Walleye Capital
ABEO icon

Walleye Capital’s Abeona Therapeutics ABEO Stock Holding History

Walleye Capital’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-160
Closed -$19K – 1847
2019
Q2 		$19K Buy
+160
New +$26.8K ﹤0.01% 1531

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BCM
Boone Capital Management Atlanta, Georgia $326M AUM 86.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Walleye Capital's ABEO Position: Q2 2025 in Review

Walleye Capital sold out of Abeona Therapeutics (ABEO) in Q2 2025, closing a stake of 183,306 shares — an estimated $873K sold.

Walleye Capital first reported a position in ABEO in Q2 2019 and held it in 9 quarters. The position peaked at $5.44M in Q3 2024. 95 funds tracked by Wall St. Rank hold ABEO as of Q2 2025.

  • Walleye Capital reported no remaining Abeona Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Walleye Capital sold 183,306 Abeona Therapeutics shares in Q2 2025, an estimated $873K.
  • Walleye Capital first reported a position in Abeona Therapeutics in Q2 2019 and held it in 9 quarters.
  • Walleye Capital's Abeona Therapeutics position peaked at $5.44M in Q3 2024.
  • 95 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2025.

Based on Walleye Capital's 13F filing for Q2 2025, filed 13 Aug 2025.